Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Molecules ; 25(4)2020 Feb 21.
Article in English | MEDLINE | ID: mdl-32098143

ABSTRACT

Studying the origin of opiate and/or opiate metabolites in individual urine specimens after consumption of cold syrups is vital for patients, doctors, and law enforcement. A rapid liquid chromatography-tandem mass spectrometry method using "dilute-and-shoot" analysis without the need for extraction, hydrolysis and/or derivatization has been developed and validated. The approach provides linear ranges of 2.5-1000 ng mL-1 for 6-acetylmorphine, codeine, chlorpheniramine, and carbinoxamine, 2.5-800 ng mL-1 for morphine and morphine-3-ß-d-glucuronide, and 2.5-600 ng mL-1 for morphine-6-ß-d-glucuronide and codeine-6-ß-d-glucuronide, with excellent correlation coefficients (R2 > 0.995) and matrix effects (< 5%). Urine samples collected from the ten participants orally administered cold syrups were analyzed. The results concluded that participants consuming codeine-containing cold syrups did not routinely pass urine tests for opiates, and their morphine-codeine concentration ratios (M/C) were not always < 1. In addition, the distribution map of the clinical total concentration of the sum of morphine and codeine against the antihistamines (chlorpheniramine or carbinoxamine) were plotted for discrimination of people who used cold syrups. The 15 real cases have been studied by using M/C rule, cutoff value, and distribution map, further revealing a potential approach to determine opiate metabolite in urine originating from cold syrups.


Subject(s)
Analgesics, Opioid/urine , Codeine/urine , Histamine Antagonists/urine , Opiate Alkaloids/urine , Adult , Analgesics, Opioid/administration & dosage , Chlorpheniramine/urine , Codeine/administration & dosage , Codeine/analogs & derivatives , Female , Forensic Medicine , Gas Chromatography-Mass Spectrometry , Humans , Male , Middle Aged , Morphine/urine , Morphine Derivatives/urine , Pyridines/urine , Young Adult
2.
R Soc Open Sci ; 6(9): 191017, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31598318

ABSTRACT

Sensitive and selective assays are demanded for quantitation of new psychoactive substances such as 4-chloroethcathinone that is a π-conjugated keto compound. Carbon dots (C-dots) prepared from L-arginine through a hydrothermal route have been used for quantitation of 4-chloroethcathinone in aqueous solution and on C-dot-functionalized papers (CDFPs). To prepare CDFPs, chromatography papers, each with a pattern of 8 × 12 circles (wells), are first fabricated through a solid-ink printing method and then the C-dots are coated into the wells. π-Conjugated keto or ester compounds induce photoluminescence quenching of C-dots through an electron transfer process. At pH 7.0, the CDFPs allow screening of abused drugs such as cocaine, heroin and cathinones. Because of poor solubility of heroin and cocaine at pH 11.0, the C-dot probe is selective for cathinones. The C-dots in aqueous solution and CDFPs at pH 11.0 allow quantitation of 4-chloroethcathinone down to 1.73 mM and 0.14 mM, respectively. Our sensing system consisting of a portable UV-lamp, a smartphone and a low-cost CDFP has been used to detect cathinones, cocaine and heroin at pH 7.0, showing its potential for screening of these drugs in crime sites.

3.
Sensors (Basel) ; 19(16)2019 Aug 15.
Article in English | MEDLINE | ID: mdl-31443204

ABSTRACT

Screening of illicit drugs for new psychoactive substances-namely cathinone-at crime scenes is in high demand. A dual-emission bovine serum albumin-stabilized gold nanoclusters probe was synthesized and used for quantitation and screening of 4-chloromethcathinone and cathinone analogues in an aqueous solution. The photoluminescent (PL) color of the bovine serum albumin-stabilized Au nanoclusters (BSA-Au NCs) probe solution changed from red to dark blue during the identification of cathinone drugs when excited using a portable ultraviolet light-emitting diodes lamp (365 nm). This probe solution allows the PL color-changing point and limit of detection down to 10.0 and 0.14 mM, respectively, for 4-chloromethcathinone. The phenomenon of PL color-changing of BSA-Au NCs was attributed to its PL band at 650 nm, quenching through an electron transfer mechanism. The probe solution was highly specific to cathinone drugs, over other popular illicit drugs, including heroin, cocaine, ketamine, and methamphetamine. The practicality of this BSA-Au NCs probe was assessed by using it to screen illicit drugs seized by law enforcement officers. All 20 actual cases from street and smuggling samples were validated using this BSA-Au NCs probe solution and then confirmed using gas chromatography-mass spectrometry. The results reveal this BSA-Au NCs probe solution is practical for screening cathinone drugs at crime scenes.


Subject(s)
Alkaloids/isolation & purification , Biosensing Techniques , Illicit Drugs/isolation & purification , Alkaloids/chemistry , Animals , Cattle , Colorimetry , Humans , Illicit Drugs/chemistry , Nanostructures/chemistry , Serum Albumin, Bovine/chemistry
4.
J Med Chem ; 55(17): 7883-91, 2012 Sep 13.
Article in English | MEDLINE | ID: mdl-22916833

ABSTRACT

A new group of hybrid nitric oxide-releasing type II antidiabetic drugs possessing a 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (13 and 18), 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (14 and 19), or nitrooxyethyl (15 and 20) moiety attached to the carboxylic acid group of the type II antidiabetic drugs nateglinide and meglitinide were synthesized. These prodrugs, based on the beneficial properties of nitric oxide (NO), were designed to reduce the risk of adverse cardiovascular events in diabetic patients. Ester prodrugs (13-15 and 18-20) exhibited appreciable oral antihyperglycemic activity comparable to the parent drugs in nonfasted diabetic rats. Systolic and diastolic blood pressure profiles validated the beneficial hypotensive properties of these prodrugs. These prodrugs released NO (1.3-72.2% range) upon incubation with either phosphate buffer solution at pH 7.4 or in the presence of serum. This new type of hybrid NO donor prodrug represents an attractive approach for the rational design of type II antidiabetic drugs with a reduced risk of contraindicated cardiovascular events.


Subject(s)
Benzamides/therapeutic use , Blood Pressure/drug effects , Cyclohexanes/therapeutic use , Hypoglycemic Agents/therapeutic use , Nitric Oxide/metabolism , Phenylalanine/analogs & derivatives , Prodrugs/therapeutic use , Benzamides/pharmacology , Cyclohexanes/pharmacology , Humans , Hypoglycemic Agents/pharmacology , Magnetic Resonance Spectroscopy , Nateglinide , Phenylalanine/pharmacology , Phenylalanine/therapeutic use , Spectrometry, Mass, Electrospray Ionization
SELECTION OF CITATIONS
SEARCH DETAIL
...